30 C
Vientiane
Friday, May 9, 2025
spot_img

Cision PR Newswire

Envision Unveils 2025 Net Zero Report at Smarter E Europe, Celebrates Third Year of Carbon Neutrality

MUNICH, May 9, 2025 /PRNewswire/ -- Envision Energy, a global leader in green technology,  released its 2025 Net Zero Action Report at the Smarter E Europe in Munich, reaffirming its commitment to climate leadership. The company achieved operational carbon neutrality for the third consecutive year since 2022 and...

Autoliv Announces Results of 2025 Annual Stockholders Meeting

DETROIT, May 9, 2025 /PRNewswire/ -- Autoliv, Inc., (NYSE: ALV) (SSE: ALIV.sdb), the worldwide leader in automotive...

Dogness Announces Entry into US$6.0 Million Private Placement

DONGGUAN, China and PLANO, Texas, May 9, 2025 /PRNewswire/ -- Dogness (International) Corporation ("Dogness"...

IMTE Announces Receipt of Deficiency Letter from Nasdaq

NEW YORK, May 9, 2025 /PRNewswire/ -- Integrated Media Technology Limited (NASDAQ: IMTE) ("IMTE"...

Endogenex™ Appoints Krissy Wright as Chief Financial Officer

Bringing finance, operational, and corporate development expertise to an experienced leadership team. MINNEAPOLIS, Jan. 15, 2025 /PRNewswire/ -- Endogenex, Inc., a clinical-stage medical device company, is...

ZTE, Nokia, and Huawei Lead ABI Research’s 5G FWA CPE Vendor Competitive Ranking

LONDON, Jan. 14, 2025 /PRNewswire/ -- A new Competitive Ranking by global technology intelligence firm ABI Research has found that ZTE is the leading 5G...

Argon Medical Expands Oncology Product Offering with Acquisition of the SeQure® and DraKon™ Microcatheters

PLANO, Texas, Jan. 14, 2025 /PRNewswire/ -- Argon Medical, a leading provider of medical device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and...

Korea’s Leading Indie Beauty Brand d’Alba, Reaches New Heights Globally with 210% Overseas Sales Surge

SEOUL, South Korea, Jan. 14, 2025 /PRNewswire/ -- Premium vegan beauty brand d'Alba has achieved significant growth in its overseas sales, rising  to approximately KRW...

ImmunoForge Receives IND Approval for Phase 2 Clinical Trial of ‘Pemziviptadil’ for DMD Cardiomyopathy Treatment from FDA, and KF1601, a chronic myeloid leukemia treatment,...

SEOUL, South Korea, Jan. 14, 2025 /PRNewswire/ -- ImmunoForge announced that it has received approval for the Phase 2 clinical trial IND for 'Pemziviptadil...